Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TELA Stock Forecast 2026-2027
$0.73
Current Price
$33.11M
Market Cap
Buy 4
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to TELA Price Targets
+343.5%
To High Target of $3.25
+172.9%
To Median Target of $2.00
+36.5%
To Low Target of $1.00
TELA Price Momentum
+28.1%
1 Week Change
-8.8%
1 Month Change
-24.0%
1 Year Change
-38.1%
Year-to-Date Change
-66.7%
From 52W High of $2.20
+46.3%
From 52W Low of $0.50
📊 TOP ANALYST CALLS
Did TELA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Tela Bio is one of their latest high-conviction picks.
Latest TELA Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, TELA has a bullish consensus with a median price target of $2.00 (ranging from $1.00 to $3.25). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $0.73, the median forecast implies a 172.9% upside. This outlook is supported by 4 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Matt O'Brien at Piper Sandler, suggesting a 36.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TELA Analyst Ratings
4
Buy
1
Hold
0
Sell
TELA Price Target Range
Low
$1.00
Average
$2.00
High
$3.25
Current: $0.73
Latest TELA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TELA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 27, 2026 | Citizens | David Turkaly | Market Outperform | Maintains | $3.00 |
| Mar 25, 2026 | Piper Sandler | Matt O'Brien | Neutral | Maintains | $1.00 |
| Mar 25, 2026 | Canaccord Genuity | Caitlin Roberts | Buy | Maintains | $2.00 |
| Mar 25, 2026 | Lake Street | Frank Takkinen | Buy | Maintains | $2.00 |
| Dec 1, 2025 | Lake Street | Frank Takkinen | Buy | Maintains | $3.00 |
| Nov 18, 2025 | Canaccord Genuity | Caitlin Cronin | Buy | Maintains | $4.00 |
| Nov 14, 2025 | Piper Sandler | Matt O'Brien | Neutral | Reiterates | $1.25 |
| Nov 14, 2025 | Citizens | David Turkaly | Market Outperform | Maintains | $5.00 |
| Mar 21, 2025 | Citizens Capital Markets | David Turkaly | Market Outperform | Maintains | $7.00 |
| Mar 21, 2025 | Piper Sandler | Matt O'Brien | Neutral | Downgrade | $2.00 |
| Mar 21, 2025 | Canaccord Genuity | Caitlin Cronin | Buy | Maintains | $7.00 |
| Nov 8, 2024 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $5.00 |
| Oct 4, 2024 | Canaccord Genuity | Caitlin Cronin | Buy | Maintains | $12.00 |
| Aug 13, 2024 | Canaccord Genuity | Caitlin Cronin | Buy | Maintains | $12.00 |
| Aug 13, 2024 | JMP Securities | David Turkaly | Market Outperform | Maintains | $12.00 |
| Aug 13, 2024 | Lake Street | Frank Takkinen | Buy | Maintains | $8.00 |
| Aug 13, 2024 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $8.00 |
| Jul 25, 2024 | Canaccord Genuity | Caitlin Cronin | Buy | Maintains | $14.00 |
| May 10, 2024 | Piper Sandler | Matt O'Brien | Overweight | Reiterates | $10.00 |
| Mar 22, 2024 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $12.00 |
Tela Bio Inc. (TELA) Competitors
The following stocks are similar to Tela Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Tela Bio Inc. (TELA) Financial Data
Valuation Metrics
Market Cap
$33.11M
Enterprise Value
$36.11M
P/E Ratio
N/A
PEG Ratio
-1.2x
Price/Sales
0.4x
Growth & Margins
Revenue Growth (YoY)
+18.2%
Gross Margin
+65.9%
Operating Margin
-31.9%
Net Margin
-48.4%
EPS Growth
+18.2%
Financial Health
Cash/Price Ratio
+155.0%
Current Ratio
4.2x
Debt/Equity
913.3x
ROE
-223.4%
ROA
-25.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Tela Bio Inc. (TELA) Business Model
About Tela Bio Inc.
What They Do
Develops innovative soft tissue reconstruction solutions.
Business Model
Tela Bio Inc. generates revenue by developing and commercializing advanced medical products for soft tissue repair, specifically targeting general surgery and hernia repair markets. The company's proprietary product lines, OviTex and OviTex PRS, utilize a combination of biologic and synthetic materials to improve clinical outcomes, allowing it to capture market share in the healthcare sector.
Additional Information
Headquartered in the United States, Tela Bio is positioned at the intersection of biotechnology and medical devices, focusing on enhancing surgical techniques and patient care through its innovative solutions. The company aims to address critical needs in the medical field, which could lead to substantial growth opportunities as demand for efficient surgical repairs increases.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
209
CEO
Mr. Antony Koblish
Country
United States
IPO Year
2019
Website
www.telabio.comTela Bio Inc. (TELA) Latest News & Analysis
Latest News
Quick Summary
TELA Bio, Inc. (NASDAQ: TELA) announced mixed results for Q4 in its recent report.
Why It Matters
Mixed results may indicate potential volatility in TELA Bio's stock, impacting investor confidence and future performance expectations. This can affect trading decisions and valuations.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
TELA Bio, Inc. held its Q4 2025 earnings call, discussing financial results and company performance. Details on revenue and future projections were shared.
Why It Matters
The earnings call provides insights into TELA Bio's financial performance, future guidance, and strategic direction, impacting stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
TELA Bio, Inc. reported its financial results for Q4 and the full year 2025 on March 24, 2026. The company specializes in soft-tissue reconstruction solutions.
Why It Matters
TELA Bio's financial results can influence stock performance, indicating growth or challenges in its market, which directly impacts investor sentiment and potential returns.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
TELA Bio, Inc. reported a quarterly loss of $0.16 per share, better than the estimated loss of $0.18 and an improvement from a loss of $0.23 per share a year ago.
Why It Matters
TELA's smaller-than-expected loss indicates improving financial performance, potentially boosting investor confidence and affecting stock valuation positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
TELA Bio, Inc. (NASDAQ: TELA) will report its Q4 and full year 2025 financial results on March 24, 2026, followed by a conference call at 4:30 p.m. ET for updates.
Why It Matters
TELA Bio's upcoming financial results announcement may affect stock performance, offering insights into its growth and market position, which could influence investor sentiment and decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
TELA Bio, Inc. announced the approval of restricted stock units covering 8,550 shares to three new employees as part of their compensation, effective February 18, 2026.
Why It Matters
The granting of restricted stock units indicates TELA Bio's commitment to attracting talent, potentially enhancing innovation and growth, which could positively impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About TELA Stock
What is Tela Bio Inc.'s (TELA) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Tela Bio Inc. (TELA) has a median price target of $2.00. The highest price target is $3.25 and the lowest is $1.00.
Is TELA stock a good investment in 2026?
According to current analyst ratings, TELA has 4 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.73. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TELA stock?
Wall Street analysts predict TELA stock could reach $2.00 in the next 12 months. This represents a 172.9% increase from the current price of $0.73. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Tela Bio Inc.'s business model?
Tela Bio Inc. generates revenue by developing and commercializing advanced medical products for soft tissue repair, specifically targeting general surgery and hernia repair markets. The company's proprietary product lines, OviTex and OviTex PRS, utilize a combination of biologic and synthetic materials to improve clinical outcomes, allowing it to capture market share in the healthcare sector.
What is the highest forecasted price for TELA Tela Bio Inc.?
The highest price target for TELA is $3.25 from at , which represents a 343.5% increase from the current price of $0.73.
What is the lowest forecasted price for TELA Tela Bio Inc.?
The lowest price target for TELA is $1.00 from Matt O'Brien at Piper Sandler, which represents a 36.5% increase from the current price of $0.73.
What is the overall TELA consensus from analysts for Tela Bio Inc.?
The overall analyst consensus for TELA is bullish. Out of 7 Wall Street analysts, 4 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $2.00.
How accurate are TELA stock price projections?
Stock price projections, including those for Tela Bio Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 17, 2026 4:01 AM UTC